@entity1311 -induced pneumonitis in @entity1 with XXXX : case series and review of the literature.

@entity632 @entity1 @entity230 @entity0 @entity649 @entity786 @entity1311 @entity358 @entity1576 @entity401 @entity221 @entity479
UNASSIGNED: @entity632 plus @entity786 followed by @entity1311 is a common adjuvant treatment for high-risk @entity0 . It has been associated with @entity358 in several case reports. We describe three @entity1 in whom @entity401 developed immediately after the first @entity1311 exposure and worsened clinically over time. All reported dyspnoea, @entity221 and progressive @entity649 . Imaging revealed diffuse @entity358 . Other causes of @entity1576 were excluded with laboratory work-up, imaging, biopsy studies and results of antibiotic treatment. The @entity1576 was reversed only after administration of high-dose @entity230 , an empirical treatment previously reported to be beneficial in similar cases. Although chemotherapy using concomitant or sequential drugs may make identification of the toxic agent difficult, we noted a clear temporal relationship between exposure to @entity1311 and the development of @entity358 . Furthermore, according to the available literature, it is less likely that a @entity1576 would be caused by either @entity786 or trastuzumab. In conclusion, clinicians should be aware of the potentially life-threatening risk of @entity358 following @entity1311 treatment. If @entity1311 is halted early and the @entity1 has good lung reserve, @entity358 can be reversed with high-dose @entity479 administration.
